Medtronic Aktie News

Medtronic stock reacted negatively to an earnings report that many Wall Street analysts found encouraging. Wells Fargo raised its price target for Medtronic to $105 per share.

Shares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow are enough to keep investors interested and if they should be.

Medtronic's top line saw growth in Q4 and full-year, but that growth disappeared in the bottom-line figures. Medtronic management was positive in its outlook for fiscal 25 with projected organic revenue growth of 4%-5%.

Medtronic plc (NYSE:MDT ) Q4 2024 Earnings Conference Call May 23, 2024 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Executive Vice President and Chief Financial Officer Brad Welnick - Vice President, Investor Relations Sean Salmon - Executive Vice President and President, Car...

Medtronic beat on sales and earnings and gave exactly the guidance that Wall Street expected. Its stock dropped today anyway.

Medtronic PLC (NYSE: MDT) is in focus on Thursday after reporting market-beating financial results for its fourth quarter.  Medtronic issues in-line guidance The stock is flat at writing because $MDT issued roughly in-line guidance for the full year.

Shares of Medtronic PLC MDT, +0.69% rallied 1.3% in premarket trading Thursday, after the medical device and therapies company reported fiscal fourth-quarter profit and revenue that rose above expectations, and lifted its dividend. Net income for the quarter to April 26 fell to $654 million, or 49 cents a share, from $1.19 billion, or 88 cents a share, in the same period a year ago.

Health tech firm Medtronic beat Wall Street estimates for quarterly profit on Thursday, aided by a post-pandemic pickup in surgical volumes at hospitals that boosted demand for its medical devices.